دورية أكاديمية
أعرض في EDS

Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer.

التفاصيل البيبلوغرافية
العنوان: Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer.
المؤلفون: Cameron S; Princess Margaret Cancer Research Centre, Toronto, ON, Canada., Deblois G; Princess Margaret Cancer Research Centre, Toronto, ON, Canada.; Institute for Research in Immunology and Cancer (IRIC), Faculty of Pharmacy, University of Montréal, Montréal, QC, H3T 1J4, Canada., Hawley JR; Princess Margaret Cancer Research Centre, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Qamra A; Princess Margaret Cancer Research Centre, Toronto, ON, Canada., Zhou S; Princess Margaret Cancer Research Centre, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Tonekaboni SAM; Princess Margaret Cancer Research Centre, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Murison A; Princess Margaret Cancer Research Centre, Toronto, ON, Canada., Van Vliet R; Princess Margaret Cancer Research Centre, Toronto, ON, Canada., Liu J; Duke University School of Medicine, Durham, NC, USA., Locasale JW; Duke University School of Medicine, Durham, NC, USA., Lupien M; Princess Margaret Cancer Research Centre, Toronto, ON, Canada. Mathieu.Lupien@uhnresearch.ca.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. Mathieu.Lupien@uhnresearch.ca.; Ontario Institute for Cancer Research, Toronto, ON, Canada. Mathieu.Lupien@uhnresearch.ca.
المصدر: Oncogene [Oncogene] 2023 May; Vol. 42 (21), pp. 1693-1703. Date of Electronic Publication: 2023 Apr 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE
أسماء مطبوعة: Publication: <2002->: Basingstoke : Nature Publishing Group
Original Publication: Basingstoke, Hampshire, UK : Scientific & Medical Division, MacMillan Press, c1987-
مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms*/pathology, Male ; Humans ; Androgens/metabolism ; Prostate/pathology ; Hypoxia/metabolism ; Castration ; Receptors, Androgen/genetics ; Cell Line, Tumor
مستخلص: Predicting and treating recurrence in intermediate-risk prostate cancer patients remains a challenge despite having identified genomic instability [1] and hypoxia [2, 3] as risk factors. This underlies challenges in assigning the functional impact of these risk factors to mechanisms promoting prostate cancer progression. Here we show chronic hypoxia (CH), as observed in prostate tumours [4], leads to the adoption of an androgen-independent state in prostate cancer cells. Specifically, CH results in prostate cancer cells adopting transcriptional and metabolic alterations typical of castration-resistant prostate cancer cells. These changes include the increased expression of transmembrane transporters for the methionine cycle and related pathways leading to increased abundance of metabolites and expression of enzymes related to glycolysis. Targeting of the Glucose Transporter 1 (GLUT1) identified a dependency on glycolysis in androgen-independent cells. Overall, we identified a therapeutically targetable weakness in chronic hypoxia and androgen-independent prostate cancer. These findings may offer additional strategies for treatment development against hypoxic prostate cancer.
(© 2023. The Author(s).)
References: Prostate. 2010 Aug;70(11):1243-54. (PMID: 20333700)
Br J Radiol. 2020 Nov 1;93(1115):20200087. (PMID: 32551913)
Nat Cell Biol. 2017 Nov;19(11):1298-1306. (PMID: 29058720)
Nat Biotechnol. 2016 May;34(5):525-7. (PMID: 27043002)
Br J Radiol. 2014 Mar;87(1035):20130753. (PMID: 24588670)
Scand J Urol. 2017 Dec;51(6):450-456. (PMID: 28762283)
J Urol. 2011 Mar;185(3):869-75. (PMID: 21239008)
Trends Biochem Sci. 2012 Sep;37(9):364-72. (PMID: 22818162)
Mol Cancer Ther. 2013 May;12(5):567-76. (PMID: 23493310)
Crit Rev Biochem Mol Biol. 2014 Jan-Feb;49(1):1-15. (PMID: 24099156)
Nature. 2017 Jan 19;541(7637):359-364. (PMID: 28068672)
Int J Cancer. 2008 Aug 15;123(4):760-8. (PMID: 18512241)
Free Radic Res. 2007 Jul;41(7):788-97. (PMID: 17577739)
Oncotarget. 2017 May 2;8(18):30328-30343. (PMID: 28416760)
Nat Methods. 2017 Jul;14(7):687-690. (PMID: 28581496)
Eur Urol. 2019 Jun;75(6):967-987. (PMID: 30342843)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
Urology. 2006 Sep;68(3):593-8. (PMID: 16979731)
Nat Rev Cancer. 2019 Nov;19(11):625-637. (PMID: 31515518)
Urology. 2010 Apr;75(4):786-92. (PMID: 19854473)
J Cell Biochem. 2013 Mar;114(3):498-509. (PMID: 22961911)
Trends Endocrinol Metab. 2018 Sep;29(9):626-637. (PMID: 30001904)
J Clin Oncol. 2019 Nov 10;37(32):2974-2986. (PMID: 31329516)
Carcinogenesis. 2013 Dec;34(12):2706-15. (PMID: 23884959)
Nat Commun. 2018 Nov 26;9(1):4972. (PMID: 30478344)
N Engl J Med. 2014 Jul 31;371(5):424-33. (PMID: 24881730)
Nat Commun. 2020 Feb 5;11(1):737. (PMID: 32024819)
J Biol Chem. 2008 Dec 26;283(52):36542-52. (PMID: 18984585)
Genome Integr. 2013 Oct 24;4(1):5. (PMID: 24152759)
J Biol Chem. 2010 Nov 26;285(48):37716-24. (PMID: 20858898)
BMC Cancer. 2020 May 7;20(1):398. (PMID: 32380981)
Cell Metab. 2006 Mar;3(3):187-97. (PMID: 16517406)
Trends Cell Biol. 2022 Sep;32(9):800-814. (PMID: 35365367)
Radiother Oncol. 2005 Aug;76(2):168-76. (PMID: 16026872)
Nat Rev Urol. 2010 Mar;7(3):136-42. (PMID: 20157302)
Hypoxia (Auckl). 2015 Dec 11;3:83-92. (PMID: 27774485)
Sci Rep. 2016 Sep 23;6:33818. (PMID: 27658807)
Cancer Res. 2013 Aug 15;73(16):5206-17. (PMID: 23786771)
Cell Metab. 2018 Feb 6;27(2):281-298. (PMID: 29129785)
Urol Oncol. 2013 Oct;31(7):1124-31. (PMID: 22226664)
Annu Rev Cell Dev Biol. 1999;15:551-78. (PMID: 10611972)
Eur Urol. 2017 Apr;71(4):618-629. (PMID: 27568654)
Curr Opin Genet Dev. 2022 Jun;74:101911. (PMID: 35487182)
Trends Cell Biol. 2017 Nov;27(11):863-875. (PMID: 28734735)
Int J Cancer. 2010 Oct 1;127(7):1535-46. (PMID: 20091868)
Cancer Cell. 2019 Mar 18;35(3):385-400.e9. (PMID: 30827887)
Eur Urol. 2018 Oct;74(4):413-419. (PMID: 29306514)
J Urol. 2006 Oct;176(4 Pt 1):1404-8. (PMID: 16952644)
Eur Urol Focus. 2017 Oct;3(4-5):487-497. (PMID: 28753804)
Am J Pathol. 2009 May;174(5):1619-28. (PMID: 19349354)
Trends Pharmacol Sci. 2017 Aug;38(8):669-686. (PMID: 28602395)
Nat Commun. 2018 Nov 21;9(1):4900. (PMID: 30464211)
Prostate Cancer Prostatic Dis. 2010 Jun;13(2):178-81. (PMID: 20038959)
Nat Genet. 2019 Feb;51(2):308-318. (PMID: 30643250)
Anal Chem. 2014 Feb 18;86(4):2175-84. (PMID: 24410464)
Clin Cancer Res. 2012 Apr 1;18(7):2108-14. (PMID: 22465832)
معلومات مُعتمدة: FRN-153234 Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre)
المشرفين على المادة: 0 (Androgens)
0 (Receptors, Androgen)
تواريخ الأحداث: Date Created: 20230405 Date Completed: 20230524 Latest Revision: 20230525
رمز التحديث: 20230525
مُعرف محوري في PubMed: PMC10202808
DOI: 10.1038/s41388-023-02680-z
PMID: 37020039
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5594
DOI:10.1038/s41388-023-02680-z